Paion AG

Established in 2000 and based in Aachen, Germany, Paion AG is a specialty pharmaceutical company dedicated to the global development and commercialization of medications for hospital-based applications in sedation, anesthesia, and critical care. Its flagship product, Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, is currently undergoing clinical trials for its potential use in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor designed to address refractory hypotension in adults with septic or other forms of distributive shock, and Eravacycline, a novel fluorocycline antibiotic targeting complicated intra-abdominal infections in adult patients. To enhance its market presence and reach, Paion AG maintains strategic partnerships and licensing agreements with entities such as Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma.